Trial
NCT01218867
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Metastatic Cancer
Intervention
Anti-VEGFR2 CAR CD8 plus PBL
Why stopped
No objective responses were observed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-10